{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Vivanza Biosciences Ltd
Why is Vivanza Biosci. falling/rising?
On 27-Nov, Vivanza Biosciences Ltd witnessed a 5.0% decline in its share price, closing at ₹2.28, reversing a four-day streak of gains amid falling investor participation and underperformance relative to its sector.
Vivanza Biosciences Faces Intense Selling Pressure Amid Consecutive Losses
Vivanza Biosciences Ltd is experiencing a pronounced sell-off, marked by a lower circuit scenario with exclusively sell orders dominating the queue. The stock’s performance today reflects severe distress selling, with no buyers stepping in to absorb the pressure, signalling heightened investor concern in the Pharmaceuticals & Biotechnology sector.
Vivanza Biosciences Surges with Unprecedented Buying Interest, Poised for Multi-Day Upper Circuit
Vivanza Biosciences Ltd has captured market attention with extraordinary buying momentum, registering a sharp price rise accompanied by an absence of sellers. This rare scenario suggests the stock may sustain its upper circuit status over multiple sessions, reflecting intense demand within the Pharmaceuticals & Biotechnology sector.
Vivanza Biosciences Surges with Unprecedented Buying Interest Amid Upper Circuit Lock
Vivanza Biosciences has witnessed extraordinary buying momentum today, with the stock hitting the upper circuit and registering only buy orders in the queue. This rare market phenomenon signals intense demand and the possibility of a sustained multi-day circuit scenario, setting the stage for close investor attention in the Pharmaceuticals & Biotechnology sector.
Vivanza Biosciences Faces Intense Selling Pressure Amid Consecutive Losses
Vivanza Biosciences Ltd, a player in the Pharmaceuticals & Biotechnology sector, is currently experiencing significant selling pressure, marked by a lower circuit scenario with only sell orders in the queue. The stock has recorded consecutive declines over the past four days, signalling distress selling and a lack of buyer interest amid a challenging market environment.
Vivanza Biosciences Faces Intense Selling Pressure Amid Consecutive Losses
Vivanza Biosciences Ltd is currently experiencing significant selling pressure, with only sell orders present in the queue today. The stock has recorded a sharp decline of 4.66% in a single day, underperforming the Sensex which posted a modest gain of 0.27%. This distress selling signals heightened investor caution in the Pharmaceuticals & Biotechnology sector.
Why is Vivanza Biosci. falling/rising?
As of 18-Nov, Vivanza Biosciences Ltd is priced at 2.36, down 4.84%. Despite recent positive trends over the past week and month, the stock has significantly underperformed year-to-date and over the past year, with declines of 32.18% and 42.16%, respectively, alongside reduced investor participation.
Vivanza Biosciences Faces Selling Pressure with 4.84% Decline, Total Loss of 9.58% in Two Days
Vivanza Biosciences Ltd is experiencing significant selling pressure, with a notable decline over the past two days. Despite recent short-term gains, the stock's long-term performance is troubling, showing substantial losses over the past year and three years, contrasting sharply with the Sensex's gains during the same periods.
Vivanza Biosciences Faces Selling Pressure with 4.98% Decline Amid Year-to-Date Loss of 28.74%
Vivanza Biosciences Ltd is experiencing notable selling pressure, with the stock facing consecutive losses. Despite a recent surge over the past week, its long-term performance reveals significant declines. Factors such as market sentiment and economic conditions may be influencing investor confidence amid the current downturn.
Why is Vivanza Biosci. falling/rising?
As of 14-Nov, Vivanza Biosciences Ltd is experiencing a significant price increase, currently at 2.61, with a recent gain of 32.49% over the past week, outperforming the Sensex. Despite a year-to-date decline of 25.00%, the stock's recent performance and increased investor participation indicate a potential turnaround.
Vivanza Biosciences Ltd Surges 9.66% Today, Achieves 32.49% Weekly Gain Amid Strong Buying Activity
Vivanza Biosciences Ltd is experiencing notable buying activity, with a recent surge in stock performance. The stock has gained significantly over the past week and is trading above key moving averages, reflecting strong buyer sentiment. However, its long-term performance remains challenged compared to broader market trends.
Why is Vivanza Biosci. falling/rising?
As of 13-Nov, Vivanza Biosciences Ltd is experiencing a price increase to 2.38, reflecting a 9.68% gain and a strong performance with a 20.81% return over the past week. Despite recent gains, the stock is down 31.61% year-to-date, underperforming the Sensex, which has risen by 8.11%.
Vivanza Biosciences Ltd Surges 9.68% Today, Achieves 20.81% Gains Over Past Week
Vivanza Biosciences Ltd is experiencing notable buying activity, with a significant daily performance and a substantial weekly increase. The stock has shown consistent gains over three days and is trading above key moving averages, despite facing longer-term challenges compared to the broader market.
How has been the historical performance of Vivanza Biosci.?
Vivanza Biosci. experienced significant financial declines, reporting net sales of 7.42 Cr in March 2025, down from 27.84 Cr in March 2024, resulting in a loss with a profit after tax of -0.67 Cr. The company faced negative cash flow and decreased total assets and liabilities during this period.
Why is Vivanza Biosci. falling/rising?
As of 12-Nov, Vivanza Biosciences Ltd's stock price is 2.17, up 9.6% recently, but it has declined 37.64% year-to-date and 49.53% over the past year. While it has outperformed its sector in the short term, long-term performance remains weak, leading to decreased investor participation.
Are Vivanza Biosci. latest results good or bad?
Vivanza Biosciences reported impressive revenue growth of 1,745.33% year-on-year in Q2 FY2026, reaching ₹55.36 crores; however, profitability remains a concern with thin margins and negative cash flow, indicating significant operational challenges ahead.
Vivanza Biosciences Reports Record Sales Amid Cash Flow Concerns and Market Momentum Shift
Vivanza Biosciences has reported its highest net sales of Rs 55.36 crore for the quarter ending September 2025, alongside peak levels in key financial metrics. Despite this positive performance, the company faces challenges with low operating cash flow, raising concerns about its financial sustainability amid recent successes.
Vivanza Biosciences Ltd Surges 9.60% Today, Accumulates 10.15% Gain Over Past Week
Vivanza Biosciences Ltd is experiencing heightened buying activity, with a notable performance increase today and over the past week. The stock has shown strong intraday interest and is trading above several moving averages, reflecting a short-term bullish trend, despite a longer-term decline year-to-date.
Vivanza Biosciences Q2 FY26: Revenue Surge Masks Deep Profitability Concerns
Vivanza Biosciences Ltd., a micro-cap pharmaceutical company with a market capitalisation of ₹8.68 crores, reported a dramatic surge in revenues for Q2 FY2026, yet the company's profitability remains razor-thin and its stock continues a precipitous decline. Net profit for the quarter stood at ₹0.56 crores, marking a spectacular 522.22% quarter-on-quarter increase from ₹0.09 crores in Q1 FY2026, whilst year-on-year growth reached an extraordinary 2,700.00% from ₹0.02 crores in Q2 FY2025. Despite this headline-grabbing profit growth, the stock has plummeted 49.53% over the past year, trading at ₹2.17 as institutional confidence remains conspicuously absent.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
